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Abstract 
 
Study Design: Longitudinal observational study. 
 
Objective: To investigate the association between the duration of pain at baseline and the 
clinical outcomes of patients with low back pain (LBP) enrolled on the North East of England 
Regional Back Pain and Radicular Pain Pathway (NERBPP). 
 
Summary of Background Data: The NERBPP is a clinical pathway based upon NICE 
guidelines (2009) for LBP of <1-year duration. Recent changes to NICE guidelines (2016), 
advocate the same management for all LBP patients regardless of pain duration.  
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Methods: Patients with LBP referred onto the NERBPP by their General Practitioner between 
May 2015 and January 2017 were included. Data from 667 patients, who provided pre-and post-
data for pain (Numerical rating scale), function (Oswestry Disability Index), quality-of-life 
(EuroQol five-dimension, five-level questionnaire), anxiety (the Generalised Anxiety Disorder 
Screener) and depression (the Patient Health Questionnaire), were analysed using a series of 
covariate-adjusted models. Patients were categorised into four groups based upon baseline pain 
duration: <3 months, ≥3 to <6 months, ≥6 months to <12 months, ≥12 months. 
 
Results: Each group showed improved outcomes greater than the minimal clinically important 
difference (MCID) for each measure as defined in NICE guidelines (2016). There was a trend 
towards better outcomes for those with shorter pain durations. The magnitude of the differences 
between the groups, in most instances, was below the MCID. For example, mean improvement 
in function for those with baseline pain duration <3 months was 20 points and 12 points for 
those of pain duration ≥12 months, both above the MCID of ≥10. 
 
Conclusions: Patients with different durations of LBP at baseline improved on the NERBPP, 
supporting the recent modification to NICE guidelines. However, those with shorter durations 
of pain may have superior outcomes in the short-term, suggesting added benefit in getting 
patients onto the pathway in the early stages of LBP. 
 
Key Words: low back pain, duration, disability, NICE guidelines. 
 
 
 
Key Points: 
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• The NERBPP is a clinical pathway based upon NICE guidelines (2009) for LBP. 
• Patients on the NERBPP of differing LBP duration at baseline improved by a clinically 
relevant amount, on a suite of outcomes, according to the minimal clinically important 
difference recommended by NICE (2016). 
• There was a trend towards better outcomes for those with shorter pain durations, 
although the magnitude of the differences between the groups, in most instances, was 
below the MCID, this would suggest that there is added benefit in getting patients onto 
the pathway in the early stages of LBP. 
 
Mini Abstract: 
 
This study found that patients with differing durations of LBP at baseline, enrolled on an 
evidence-based clinical pathway, improved by the minimal clinically important difference 
recommended by NICE (2016) on a suite of outcome measures. However, those with shorter 
durations of pain may have superior outcomes in the short-term. 
 
Introduction 
Low back pain (LBP) presents a considerable challenge to health care systems globally. It is 
associated with the longest duration of time spent with disability in many countries.1 In 
addition, LBP represents a significant economic burden to individuals, health systems and 
society including health care resource utilisation and lost work productivity. 2-4  
 
The updated National Institute for Health and Care Excellence (NICE) guidelines (2016) have 
been refocused away from traditional duration-based classification of LBP. These guidelines 
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now advocate the same management for all LBP patients regardless of duration of pain, 
recommending instead the use of a risk stratification approach to classify patients.5 This 
approach contrasts with many other guidelines where the management of patients with acute 
pain differs from those with chronic pain.6,7 In-order to support any change in clinical practice, 
it should demonstrate better outcomes and be valued by patients.8  
 
Currently, there is little empirical data to support this change in clinical practice to an approach 
that encourages the same management of all LBP patients regardless of duration of pain. Only 
one study has directly investigated the role of baseline pain duration on clinical outcome. Dunn 
and Croft9 demonstrated that patients with a longer pain duration (≥3 years) at baseline were 
associated with poorer clinical outcomes. This indicates that baseline pain duration may be of 
importance when considering clinical outcome, however, this work looked at patient outcomes 
following a broad battery of usual care from their GP. As it is difficult to know exactly what 
was delivered in this usual care, it is difficult to relate back to the modification of the NICE 
guidelines regarding pain duration. 
 
The North East of England Regional Back Pain and Radicular Pain Pathway (NERBPP) is a 
clinical manifestation of the NICE LBP guidelines (2009). It has been implemented in first 
adopter sites in clinical commissioning group regions of the North East of England since 2015. 
Although targeted originally at patients with acute pain, patients with LBP of varying pain 
duration access the pathway. It could be proposed that if the recent shift in NICE guidelines is 
justified, to treat patients of different pain duration similarly, then patients with different pain 
durations should have similar outcomes on the NERBPP. The aim of this study was to 
investigate the association between the duration of pain at baseline and the clinical outcomes 
of patients with LBP enrolled on the NERBPP. 
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Methods 
Study design  
This study is part of a large-scale evaluation of the implementation of the NERBPP. Ethical 
approval for the evaluation was obtained from Teesside University (Reference number 
R179/15). This was a longitudinal, observational study of patients with LBP, over the age of 
18, referred onto the NERBPP by their GP between May 2015 and January 2017 (n=6102).  
 
The pathway was not initially intended for patients with more longstanding pain. Thus, GPs 
were encouraged to refer onto the pathway: acute, new onset, LBP patients and those 
experiencing a flare up of a new attack of LBP with at least 6 months since their last attack. 
The GP screened patients using the STarT Back stratification tool.10 Those classified as 
moderate to high risk of poor outcome on the STarT Back tool were referred to a triage and 
treat practitioner (T&TP) (specially trained nurses and physiotherapists). They assessed all 
participants and referred them for investigations and/or core therapies (physiotherapy 
incorporating exercise, manual therapy or acupuncture). There was also the option to refer to a 
100-hour residential, combined physical and psychological therapies program for a small 
number of patients. Patients included for analysis in this study may have received some 
combination of these interventions. 
 
Data collection 
Baseline data collected at the initial T&TP appointment included socio-demographic variables 
age, sex and socioeconomic status. The date of onset of the patient’s symptoms was extracted 
from the T&TP notes and uploaded to System 1 (electronic patient records system). Duration 
of baseline pain was calculated by subtracting “date of onset” from “date of GP referral” onto 
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the pathway. Patients were categorised into four groups based upon their calculated baseline 
pain duration: <3 months, ≥3 months to <6 months, ≥6 months to <12 months, ≥12 months.  
 
Baseline information was gathered on the STarT Back screening tool score and a battery of 
standardised, valid and reliable patient reported outcome measures (PROMs). A series of 
standard outcome measures is recommended to enable easier comparison of results of clinical 
studies to be made.11 Pain intensity was measured using the 11-point numerical rating scale 
(NRS).12 The level of functional disability was determined using the Oswestry Disability Index 
(ODI).13 The EuroQol five-dimension, five-level questionnaire (EQ-5D-5L) was used to 
measure quality of life,14 the Generalised Anxiety Disorder Screener (GAD-7)15 and the Patient 
Health Questionnaire (PHQ-9)16 were used to assess anxiety and depression, respectively. Data 
collected from the GAD-7 and PHQ-9 were analysed for numerical and categorical scores. The 
GAD-7 numerical was scored from 0-21, while the PHQ-9 was scored from 0-27. The GAD-7 
and PHQ-9 categorical scales ranged from: 0= ‘Not Difficult at all’ to 3= ‘Extremely Difficult’. 
 
On discharge, patients were asked to complete all PROMS and give their overall perception of 
improvement on a six-point Likert-based Global Subjective Outcome Scale (GSOS), the 
descriptors for which ranged from ‘completely better’ to ‘worse’.17 Patients were asked to rate 
their satisfaction with the service they had received using the NHS Friends and Family Test 
(FFT); a six-point scale ranging from ‘extremely likely’ to ‘don’t know’.18 For an indication of 
their readiness to self-manage, patients were asked the question: “do you feel ready to self-
manage your back pain?”  The response was given using a 0-10-point continuous scale, with 0 
representing ‘not confident’ and 10 representing ‘totally confident’. This scale was adapted 
from work by Lorig.19  
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Analysis 
Initial analysis involved grouping participants into one of three categories: those discharged at 
their initial appointment (same-day discharge (SDD)), those discharged following an initial 
appointment and at least one further appointment (standard discharge (StD)) and those 
discharged due to non-attendance (non-attender (NA)). The StD group was the only group for 
whom outcome data was routinely collected and therefore included for analysis in this study. 
Before commencing statistical analysis, the data were checked for any data entry errors; 
statistical analysis was carried out using SPSS for Windows (2012). 
 
Outcome data included the pre and post PROMS following management on the NERBPP. 
Change scores for pain, disability, anxiety, depression and general health status were calculated 
by subtracting initial scores from discharges scores for each patient that completed follow-up 
data. The outcomes for the four duration groups were compared using a series of covariate-
adjusted models. The outcome measures of interest were the PROMS mentioned previously, 
duration category was the independent variable and the following were included as covariates: 
baseline scores, age, sex and socioeconomic status.20 An ordinal, covariate-adjusted model was 
used for categorical data. For PROMs, the minimal clinically important difference (MCID), as 
defined by the NICE (2016) guidelines,5 was used to establish if clinically relevant 
improvements were observed in mean change scores. For continuous outcome measures, the 
MCID is defined as a 10% improvement of a measure of clinical benefit; for the EQ-5D, 0.03 
was used as a MCID.5  
 
Continuous data were presented as mean (standard deviation) while categorical data were 
presented as percentage, mean (standard deviation) or median (interquartile range). 
Comparisons between the characteristics of the discharge categories were made using a 
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singlefactor general linear model (GLM) for continuous data, and the Kruskal-Wallis H test 
and/or Chi Square test for categorical data. Statistical significance was set at p< 0.05. 
 
Results 
Of the 6102 participants, who had baseline data present, 2268 were excluded from the analysis, 
as they were not yet discharged from the pathway. Of those that were discharged, 2071 were in 
the StD group, 1147 were SDD and 616 were categorised as NA. As outcome data was not 
routinely collected from SDD and NA, they were not included in the analysis.  
 
The baseline participant characteristics for the three discharge categories are shown in Table 1. 
Although there were statistically significant differences, the main clinically relevant differences 
between the categories were that NA were younger and from lower socioeconomic 
backgrounds. Participants in the SDD category had the lowest levels of pain, anxiety and 
depression, the highest proportion of patients in the low risk grouping on the STarT Back, and 
the highest levels of function and quality-of-life. 
Within the StD category, those that provided outcome data were labelled as complete cases 
(n=667), while those that did not provide any outcome data were labelled as incomplete cases 
(n=1404). Although the trend for baseline outcome measures for the incomplete cases were 
statistically poorer on all measures, these differences were not clinically relevant 
(supplementary table A). 
 
Table 2 shows the mean changes in outcome measures when grouping participants in the StD 
group into one of the four pain duration categories from <3 months to ≥12 months. For the 
entire battery of PROMs, all four groups improved by clinically relevant amounts. There was a 
trend towards better outcomes for those with a shorter duration of pain.  
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On the GSOS all groups reported improvements in their overall outcome on discharge. There 
was a significant difference between the groups, those with shorter pain durations reporting 
greater improvement. For example, 64.8% of those in the <3 months category reported being a 
lot better/completely better, compared to 44.4% in those groups with longer durations of pain. 
Over 89% of those in the ≥12 months group, and 93% of those in the <3 months group, were 
extremely likely/likely to recommend the service to a friend or relative; the differences between 
the groups were not statistically significant (Table 3). 
 
The baseline values for the PROMs for the pain duration groups are shown in Supplementary 
Table B. There were no statistically significant or clinically relevant differences between 
groups.  
 
 
 
Discussion 
Results of the analysis show that regardless of the duration of pain, all LBP patients enrolled 
on the NERBPP improved by a clinically relevant amount, for a suite of clinical outcomes, 
according to the MCID recommended by NICE (2016). Patients with a shorter duration of pain 
showed a trend towards statistically better outcomes, although the magnitude of the differences 
between the groups were, in most instances, below the MCID. Stapleton et al.21 highlighted the 
importance of clinically significant results, rather than interpreting a p-value in isolation. 
 
A key research priority in LBP is the translation of high-quality research findings into clinical 
practice.22 The NERBPP fulfils this research priority, as it is the implementation of evidence-
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based, NICE guidelines23 directly into clinical practice. A major change in the revised NICE 
(2016) guidelines compared to the 2009 guidelines is the emphasis on duration of symptoms. 
The 2009 guidelines focused on those with LBP of more than six weeks and less than one-year 
duration, while the 2016 guidelines make no distinction based upon duration of symptoms. 
Although the NERBPP was initially intended to target patients with acute pain, the majority of 
patients referred onto the pathway did not meet the set duration criteria provided to GP’s. The 
reasons for this are unclear, though it may stem from the perseverance of pre-existing local 
practice, which traditionally referred all patients with LBP irrespective of duration of symptoms 
and the ubiquitous challenge of defining a patient’s duration of symptoms in the traditional 
dichotomy of acute and chronic. Regardless of the reason, this referral pattern points towards 
the practical challenge that is operationalising a pathway specifically for acute or chronic pain 
patients, supporting the change in guidelines from a practical perspective. Additionally, the 
findings of this study provide some support to the change in NICE guidelines, as LBP patients 
of all pain durations improved by the MCID for all outcomes following management on the 
NERBPP. 
 
In contrast to this, however, is the fact that for some pain duration categories, the difference 
between groups, for some outcomes, was greater than the MCID, with 95% CI for the mean 
change not overlapping. For example, pain reduction in the <3 month group was -3.3 (-3.7, -
2.8) compared to -2.0 (-2.3, -1.6) in the ≥12 month group. Using the NICE MCID of 1 on the 
0-10 pain NRS, it indicates that those with more chronic pain improve by a clinically lower 
amount. This suggests that there is added value in getting patients onto the pathway in the early 
stages of back pain. Overall, although there appears to be benefit for all pain durations, there is 
room to explore the differential benefits for the subgroups of pain duration categories.  
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There is a lack of clearly defined criteria to classify chronic pain,9,24,25 with increasing evidence 
demonstrating the problems of describing chronic pain based upon duration alone.25,-27 Dunn 
and Croft9 highlight there is little specific research on the association between duration and 
outcome, beyond the standard dichotomy. Their work found that in LBP patients, duration of 
pain is a predictor of outcome, regardless of baseline severity and psychological status. A key 
difference between the current study and that of Dunn and Croft9 is that their participants 
received usual care from their GP, while participants in this study were managed on the 
evidence-based NERBPP. 
 
Strengths of the current study include the use of real life clinical data, gathered as part of 
everyday clinical practice and the comprehensive number of standardised, valid and reliable 
PROMs reported. Outcome data was routinely collected only from participants in the StD 
category. Although there were statistically significant differences between the baseline 
participant characteristics for the three discharge categories, the main clinically relevant 
differences were in keeping with clinical expectations of these groups. Baseline values were 
also added to the statistical model as a covariate, so group differences were adjusted for this 
factor. Those in the NA category were younger and from lower socioeconomic backgrounds, 
common characteristics of those less likely to attend appointments.28 Participants in the SDD 
category were found to have a better clinical profile, including lower levels of pain, anxiety and 
depression, and the highest proportion of patients in the low risk grouping on the STarT Back. 
This correlates with the aims of the NERBPP, using the STarT Back tool, to stratify the 
management of patients and prevent over-treatment of low-risk patients.29 Within the StD 
category, those that did not provide outcome data, i.e. the incomplete cases, had statistically 
poorer baseline measures, however, these differences were small and of questionable clinical 
relevance. 
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Another strength of this study is that although the duration of symptoms were categorised into 
four pain duration groups, analysis of the data was initially attempted using a continuous 
method. However, the data was heavily skewed towards more acute durations of less than 3 
months, demonstrating that this would be an inappropriate way to analyse the data, hence, a 
categorised approach was adopted. 
 
A limitation of this study was the data collection process regarding the onset of LBP symptoms. 
Duration of symptoms was obtained from the patient’s notes uploaded to System 1 by the 
T&TP. As no standardised question was used to obtain this information, there was no 
clarification as to whether this referred to the patient’s first onset of LBP or whether it referred 
specifically to their current episode. Patients may have answered this question differently with 
more precise questioning. Dunn et al.30 highlight the importance of the wording of questions, 
as this could lead to misclassification of patients. Standardised definitions of episode of pain 
have been proposed to ensure that the question accurately represents what is being asked;9,31 
such definitions could be used in the future for more consistency. 
 
Future research could explore whether the clinical improvements seen in this study, for the four 
pain duration categories, are maintained over the longer term, as it is known that LBP is 
characterised by variability and change.32  
 
Conclusions: 
This study found that patients of differing LBP duration improved by clinically relevant 
amounts on the NERBPP. However, those with shorter durations of pain may have superior 
outcomes in the short-term. 
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Table 1: Participant characteristics for group discharge categories. 
Data are mean (SD), percentage (%), or median (IQR). Not all participants provided data for each of the variables, the total for 
each variable is provided. STarTback risk= dichotomy of scores:  low risk= score of 0-3, score of >3= at risk. (n=3446). NRS= 
Numerical Rating Scale (n=2173). ODI= Oswestry Disability Index (n=2488). EQ-5D= EuroQol five-Dimension 
Questionnaire (n=2555), VAS= Visual Analogue Scale (n=2496). GAD-7= Generalised Anxiety Disorder Screener (n=2197). 
PHQ-9= Patient Health Questionnaire (n=2208). GAD-7 categorical= data from question 8 on the GAD-7 (n=2343); PHQ-9 
categorical data from question 10 on PHQ-9 (n=2380). *Higher NRS, ODI, GAD-7 and PHQ-9 scores are worse. # Lower EQ-
5D and EQ-5D VAS scores are worse. 
 
 Standard 
n= 2071 
Same-day 
n= 1147 
Non-attender 
n= 616 
p-value 
Age (years) 52.8 (16.2) 52.1 (15.9) 44.5 (14.6) <0.001 
Sex (female) 59.3 % 57.5 % 61.0 % 0.340 
Socioeconomic Status (1-10) 5 (1-8) 5 (1-8) 4 (1-7) <0.001 
STarTBack score (0-9) 6.4 (1.8) 5.9 (2.0) 6.5 (1.9) <0.001 
STarTBack risk (low risk) 7.7 % 13.5 % 7.6 % <0.001 
Symptom duration (months) 42 (78) 39 (80) 43 (73) 0.484 
Pain NRS (0-10)* 6.9 (1.8) 6.5 (2.1) 7.1 (1.7) <0.001 
ODI (0-100%)* 44.6 (17.7 37.9 (19.4) 43.9 (16.4) <0.001 
EQ-5D (1 to -0.594) # 0.4 (0.3) 0.5 (0.3) 0.5 (0.3) <0.001 
EQ-5D VAS (0-100%) # 52.5 (24.8) 59.6 (22.4) 53.6 (23.0) <0.001 
GAD-7 (0-21)* 8.2 (6.5) 6.7 (6.5) 9.4 (6.4) <0.001 
PHQ-9 (0-27)* 9.6 (7.3) 7.7 (7.2) 10.8 (7.6) <0.001 
GAD-7 categorical * 1.1 (0.9) 
1 (1-2) 
0.9 (0.9) 
1 (0-1) 
1.1 (0.8) 
1 (1-2) 
<0.001 
PHQ-9 categorical * 1.1 (0.9) 
1 (0-2) 
0.9 (0.9) 
1 (0-1) 
1.1 (0.9) 
1 (0-2) 
<0.001 
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Table 2: Mean change for patient reported outcome measure for standard discharge patients, categorisation based on duration of pain. 
Variable n < 3 months  ≥3-<6 months ≥6-<12 months ≥12 months p-value 
Pain NRS (0-10) * 407 -3.3 (-3.7, -2.8) a -3.1 (-3.6, -2.6) b -2.4 (-3.0, -1.8) c -2.0 (-2.3, -1.6)  0.06 
ODI (0-100%) * 491 -20 (-23, -17) a -18 (-21, -15) b -15 (-19, -12) c -12 (-14, -10) 0.05 
EQ-5D Value (1 to -0.594) # 500 0.3 (0.2, 0.3) a 0.2 (0.2, 0.3) b 0.2 (0.2, 0.3) 0.2 (0.1, 0.2) 0.04 
EQ-5D VAS (0-100%) # 507 14.3 (10.9, 17.7) 17.7 (14.0, 21.4) b 13.5 (9.2, 17.8) 10.8 (8.0, 13.5) 0.02 
GAD-7 (0-21) * 401 -3.7 (-4.5, -2.9) a -2.9 (-3.8, -2)  -2.6 (-3.7, -1.6) -2.1 (-2.7, -1.4) 0.24 
PHQ-9 (0-27) * 409 -4.4 (-5.3, -3.6) a -3.8 (-4.7, -2.8) -2.9 (-4.0, -1.7) c -2.8 (-3.5, -2.1) 0.24 
GAD-7 categorical* 374 0.5 (0.7)  
0 (0-1) 
0.4 (0.6) 
0 (0-1) 
0.6 (0.8) 
0 (0-1) 
0.7 (0.7) 
1 (0-1) 
<0.01 
PHQ-9 categorical* 534 0.4 (0.6)  
0 (0-1) 
0.3 (0.5) 
0 (0-1) 
0.6 (0.7) 
0 (0-1) 
0.6 (0.8) 
0 (0-1) 
0.01 
Self-management # 638 6.4 (6.0-6.8) 6.8 (6.3-7.3) 6.3 (5.8-6.8) 5.9 (5.6-6.2) 0.17 
Data are Mean change (95% Confidence Interval Lower, Upper Bound), Mean (SD) and Median (IQR) by use of covariate adjusted models for: age, sex, socioeconomic status and baseline score 
for the outcome measure. a: statistically significant better outcome at < 3 months than at ≥12 months. b: statistically significant better outcome at ≥3-<6 months than at ≥12 months. c: statistically 
significant better outcome at <3 months than at ≥6- <12 months. Not all participants provided data for each of the variables, numbers are given for each duration category (n= < 3 months; ≥3-<6 
months; ≥6<12 months; ≥12 months) NRS= Numerical Rating Scale (n=106; 86; 59; 156). ODI= Oswestry Disability Index (n= 125; 104; 75; 187). EQ-5D= EuroQol five-Dimension Questionnaire, 
Value (n=128; 108; 77; 187) VAS= Visual Analogue Scale (n= 127; 108; 79; 193). GAD-7= Generalised Anxiety Disorder Screener (n=103; 84; 60; 154). PHQ-9= the Patient Health Questionnaire 
(n=100; 85; 62; 162). GAD-7 categorical= data from question 8 on the GAD-7 (n=86; 85; 52; 151); PHQ-9 categorical data from question 10 on PHQ-9 (n=128; 108; 81; 217). Self-management 
(n= 168; 125; 93; 252) *Higher NRS, ODI, GAD-7 and PHQ-9 scores are worse. #Lower EQ-5D Value, EQ-5D VAS and self-management scores are worse. 
 
 
Table 3: Categorical data for GSOS and FFT, categorisation based on duration of pain. 
 < 3 months ≥3-<6 months ≥6-<12 months ≥12 months p-value 
GSOS  n=162 n=116 n=91 n=241 <0.01 
Completely better 10.5% 4.3% 3.3% 5.0%  
A lot better 54.3% 56.0% 42.9% 39.4%  
Moderately better 14.8% 19.0% 22.0% 16.2%  
A little better 9.9% 10.3% 17.6% 14.5%  
Same 8% 7.8% 13.2% 21.6%  
Worse 2.5% 2.6% 1.1% 3.3%  
FFT  n=166 n=122 n=97 n=250 0.22 
Extremely likely 75.3% 71.3% 66.0% 62.0%  
Likely 18.7% 22.1% 24.7% 27.6%  
Neither likely or unlikely 1.2% 4.9% 5.2% 5.2%  
Unlikely 1.2% 0.0% 1.0% 0.8%  
Extremely unlikely 2.4% 0.8% 0.0% 1.2%  
Don’t know  1.2% 0.8% 3.1% 3.2%  
 GSOS= Global Subjective Outcome Scale. FFT= Friends and Family Test
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Supplementary Table A: Participant characteristics for standard discharge patients who 
have and have not provided outcome data. 
Data 
are 
mean score (SD), percentage (%), or median (IQR). Not all participants provided data for each of the variables, the total for 
each variable is provided. STarTback risk= dichotomy of scores:  low risk= score of 0-3; score of >3= at risk (n=1952). NRS= 
Numerical Rating Scale (n=1271). ODI= Oswestry Disability Index (n=1493). EQ-5D= EuroQol five-Dimension 
Questionnaire, with Value (n=1524), with VAS= Visual Analogue Scale (n=1506). GAD-7= Generalised Anxiety Disorder 
Screener (n=1306). PHQ-9= Patient Health Questionnaire (n=1314). GAD-7 categorical= data from question 8 on the GAD-7 
(n=1399); PHQ-9 categorical data from question 10 on PHQ-9 (n=1427). * Higher NRS, ODI, GAD-7 and PHQ-9 scores are 
worse. # Lower EQ-5D and EQ-5D VAS scores are worse.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Incomplete cases 
(n=1404) 
Complete case 
(n=667) 
p-value 
Age (years) 52.0 (16.0) 54.7 (16.5) <0.001 
Sex (female) 60.1% 57.7 % 0.300 
Socioeconomic Status 5 (1-8) 5 (1-8) 0.261 
Startback score  6.4 (1.9) 6.3 (1.8) 0.103 
Startback risk (low risk) 8.0% 7.2% 0.528 
Symptom duration (months) 43 (79) 37 (74) 0.073 
Pain NRS (0-10) * 7.0 (1.7) 6.8 (1.8) 0.048 
ODI (0-100%) * 45.7 (17.9) 42.9 (17.2) 0.002 
EQ-5D Value (1 to -0.594) # 0.4 (0.3) 0.4 (0.3) 0.017 
EQ-5D VAS (0-100%) # 50.6 (21.2) 55.1 (28.8) 0.001 
GAD-7 (0-21) * 8.6 (6.7) 7.4 (6.2) 0.001 
PHQ-9 (0-27) * 10.3 (7.3) 8.7 (7.2) <0.001 
GAD-7 categorical * 1.2 (0.9) 
1 (1-2) 
1.1 (0.8) 
1 (0-2) 
0.029 
PHQ-9 categorical * 1.2 (0.9) 
1 (1-2) 
1.0 (0.8) 
1 (0-1) 
0.002 
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Supplementary Table B: Baseline values for patient reported outcome measures, categorisation based on duration of pain. 
Variable n < 3 months  ≥3-<6 months ≥6-<12 months ≥12 months p-value 
Pain NRS (0-10) * 407 6.6  6.7  7.2  6.9  0.15 
ODI (0-100%) * 491 43.0  40.0  42.4  42.9  0.42 
EQ5D Value (1 to -0.594) # 500 0.44  0.49  0.43  0.45  0.43 
EQ5D VAS (0-100%) # 507 59.2  57.5  56.0  53.7  0.42 
GAD7 (0-21) * 401 6.4  6.4  6.5  7.4  0.50 
PHQ9 (0-27) * 409 8.4  7.6  6.9  9.0  0.16 
GAD-7 categorical* 374 1.1 1.0 1.0 1.0 0.55 
PHQ-9 categorical* 534 1.1 0.9 0.8 1.0 0.16 
Data are Mean score. Not all participants provided data for each of the variables, numbers are given for each duration category (n= < 3 months; ≥3-<6 months; ≥6<12 months; ≥12 months) NRS= 
Numerical Rating Scale (n=106; 86; 59; 156). ODI= Oswestry Disability Index (n= 125; 104; 75; 187). EQ-5D= EuroQol five-Dimension Questionnaire, Value (n=128; 108; 77; 187) VAS= Visual 
Analogue Scale (n= 127; 108; 79; 193). GAD-7= Generalised Anxiety Disorder Screener (n=103; 84; 60; 154). PHQ-9= the Patient Health Questionnaire (n=100; 85; 62; 162). GAD-7 categorical= 
data from question 8 on the GAD-7 (n=86; 85; 52; 151); PHQ-9 categorical data from question 10 on PHQ-9 (n=128; 108; 81; 217). *Higher NRS, ODI, GAD-7 and PHQ-9 scores are worse. 
#Lower EQ-5D Value, EQ-5D VAS and self-management scores are worse. 
Duration of LBP on Outcomes 
 21 
   Duration of LBP on Outcomes  
 22 
 
